Celularity Inc
NASDAQ:CELU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Compania Minera Autlan SAB de CV
BMV:AUTLANB
|
MX |
|
C
|
Crown Lifters Ltd
NSE:CROWN
|
IN |
|
K
|
Kid ASA
OSE:KID
|
NO |
|
D
|
Daewoo Electronic Components Co Ltd
KRX:009320
|
KR |
|
A
|
Autoline Industries Ltd
NSE:AUTOIND
|
IN |
|
ASE Technology Holding Co Ltd
NYSE:ASX
|
TW |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
US |
|
88 Energy Ltd
ASX:88E
|
AU |
|
COPT Defense Properties
NYSE:CDP
|
US |
Celularity Inc
Research & Development
Celularity Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celularity Inc
NASDAQ:CELU
|
Research & Development
-$15.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Celularity Inc
Glance View
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).
See Also
What is Celularity Inc's Research & Development?
Research & Development
-15.5m
USD
Based on the financial report for Sep 30, 2025, Celularity Inc's Research & Development amounts to -15.5m USD.
What is Celularity Inc's Research & Development growth rate?
Research & Development CAGR 3Y
45%
Over the last year, the Research & Development growth was -17%. The average annual Research & Development growth rates for Celularity Inc have been 45% over the past three years .
